NCT01370629 - Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049) | Biotech Hunter

Enrollment

2,015

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 5, 2018

Study Completion Date

May 8, 2018

Conditions

Atrial Fibrillation

Interventions

DRUG

Vernakalant

Prescribed at the discretion of the physician in accordance with their usual practice

Trial Locations (6)

Medizinische Universitat Wien, Vienna

Aalborg

Kuopio Hospital, Kuopio

St-Vincenz Krankenhaus, Paderborn

Hospital Universitario Severo Ochoa, Madrid

Skanes Universistetssjukhus, Malmo